Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA (“Ecstasy”) and MDA (“Love”)

作者: Ruth McNamara , Aoife Kerans , Barry O'Neill , Andrew Harkin

DOI: 10.1016/J.NEUROPHARM.2005.08.006

关键词:

摘要: Abstract The present study determined the effect of caffeine co-administration on core body temperature response and long-term serotonin (5-HT) loss induced by methylenedioxymethamphetamine (MDMA; “Ecstasy”) its metabolite methylenedioxyamphetamine (MDA; “Love”) to rats. In group-housed animals, (10 mg/kg) enhanced acute toxicity MDMA (15 mg/kg) MDA (7.5 mg/kg), resulting in an exaggerated hyperthermic (+2 °C for 5 h following +1.5 °C 3 h MDA) when compared (+1 °C 3 h) 1 h) alone. Co-administration with or was also associated increased lethality. To reduce risk lethality, doses were reduced further experiments animals housed individually. examine effects repeated administration, received (5 mg/kg) without twice daily 4 consecutive days. alone hypothermia (fall 1 2 °C) over treatment resulted hyperthermia (increase up 2.5 °C) administration treated MDMA/MDA This not observed unlike + MDA, where obtained 4 day period. addition, 4 weeks after last treatment, (but MDMA) a reduction 5-HT 5-hydroxyindole acetic acid (5-HIAA) concentrations frontal cortex (to 61% 58% control, respectively), hippocampus (48% 60%), striatum (79% 64%) amygdala (63% 37%). However, (2.5 mg/kg) co-administered four times 2 days both hippocampal (reduced 68% control). Neither nor significant regional 5-HIAA administration. conclusion, promotes MDA. is serious drug interaction, which could have important health consequences recreational users.

参考文章(35)
Terrence J. Monks, Fengju Bai, R. Timothy Miller, Serrine S. Lau, Serotonergic neurotoxicity of methylenedioxyamphetamine and methylenedioxymetamphetamine. Advances in Experimental Medicine and Biology. ,vol. 500, pp. 397- 406 ,(2001) , 10.1007/978-1-4615-0667-6_62
Una D. McCann, Victoria Eligulashvili, George A. Ricaurte, Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine Progress in Neuro-psychopharmacology & Biological Psychiatry. ,vol. 22, pp. 1087- 1102 ,(1998) , 10.1016/S0278-5846(98)00063-3
Andrew Harkin, Thomas J. Connor, Jane Mulrooney, John P. Kelly, Brian E. Leonard, Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. Life Sciences. ,vol. 68, pp. 1367- 1382 ,(2001) , 10.1016/S0024-3205(00)01039-0
K.M Hegadoren, G.B Baker, M Bourin, 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neuroscience & Biobehavioral Reviews. ,vol. 23, pp. 539- 553 ,(1999) , 10.1016/S0149-7634(98)00046-3
UNA D. McCANN, GEORGE A. RICAURTE, Domenic A. Ciraulo, Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users. Journal of Clinical Psychopharmacology. ,vol. 11, pp. 302- 305 ,(1991) , 10.1097/00004714-199110000-00005
Una D. McCann, Alison Ridenour, Yavin Shaham, George A. Ricaurte, Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans Neuropsychopharmacology. ,vol. 10, pp. 129- 138 ,(1994) , 10.1038/NPP.1994.15
Kirsten C Morley, Jason E Gallate, Glenn E Hunt, Paul E Mallet, Iain S McGregor, Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine (“Ecstasy”) European Journal of Pharmacology. ,vol. 433, pp. 91- 99 ,(2001) , 10.1016/S0014-2999(01)01512-6
Michael P. Johnson, Andrew J. Hoffman, David E. Nichols, Effects of enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices European Journal of Pharmacology. ,vol. 132, pp. 269- 276 ,(1986) , 10.1016/0014-2999(86)90615-1
Robert W. Derlet, Joe C. Tseng, Timothy E. Albertson, Potentiation of cocaine and d-amphetamine toxicity with caffeine. American Journal of Emergency Medicine. ,vol. 10, pp. 211- 216 ,(1992) , 10.1016/0735-6757(92)90211-F